Zedira licenses ZED-101 for celiac disease therapy to Dr. Falk Pharma in Europe
30-Nov-2011
- Germany
Under the terms of the agreement, Dr. Falk Pharma GmbH takes over preclinical and clinical development as well as marketing of the drug.
Zedira receives an upfront payment and may receive further milestone payments as well as royalties.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.